Beamtree Holdings Ltd · ASX:BMT
Beamtree — Shareholder Meeting (November 2022)
23 slides from Beamtree's shareholder meeting presentation, Nov 24, 2022
Slide 1: Annual General Meeting – Addresses and Presentation
Beamtree Holdings Limited (ASX: BMT) ASX Announcement For personal use only Sydney, 24 November 2022 Annual General Meeting –Addresses and Presentation Beamtree Holdings Limited (“Beamtree” or “the Company”) (ASX: BMT), advises that the 2022 Annual General Meeting (AGM) will be held today, Thursday,
Slide 2: Chairman and CEO Address to the AGM
Beamtree Holdings Limited (ASX: BMT) ASX Announcement For personal use only Sydney, 24 November 2022 Chairman and CEO Address to the AGM Introduction Good afternoon ladies and gentlemen. Welcome to the 2022 Annual General Meeting for Beamtree Holdings Limited. It is 4.00pm, we have a quorum present,
Slide 3: Performance overview
On behalf of the Board and all our people, I thank our customers for their business and you, our shareholders, for your faith and support. For personal use only I will now pass over to Tim Kelsey to provide an update on the business achievements in FY22, the latest trading update for this current ye
Slide 4: CEO address: coding assistance and analytics updates
Coding assistance and data quality revenue grew 11% in Q1 FY23. Middle East: Beamtree has agreed a partnership with Lean, a government-owned technology solutions company in the Kingdom of Saudi Arabia, to promote PICQ® and support the rollout For personal use only of Beamtree software to public
Slide 5: FY22 Annual General Meeting
Beamtree FY22 Annual General Meeting 24th November, 2022
Slide 6: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASXBMT) andis current at the date of the presentation, 24 August 2022. This presentation may contain statements that are, or may be deemed to be, forward looking state
Slide 7: Board of Directors
Board of Directors Mike Hill Chairman of the Board Andrew Gray Non-Executive Director core Non-Executive Director aN Pe Brad Lancken Non-Executive Director Stephen Borness Non-Executive Director Non-Executive Director a] Emma Gray Non-Executive Director @ NAN
Slide 8: AGM Agenda
AGM Agenda ersopnal use-only Chair's Address CEO Update Order of Business Q&A ¢ FY23 Update
Slide 9: Creating a better future for health
-Beamtree’ CSreating a better future for health Ce provide Al decision support and data ights solutions with the aim of turning data into insights and action through automation. We believe it starts with better data and ends Co care — and that ‘better has no limit’ erson
Slide 10: Beamtree's History
Beamtree’s History Knowledge Systems ¢ Est. 1999 - Listed 2019 e leDown RippleDown Auaitor Expert - Acq. 2021 2 isc! ersonal us
Slide 11: Supporting Healthcare Providers Globally
Supporting Healthcare Providers Globally y support 175+ clients 0 operate across le 6 ae »V°! Continents Countries go ersona! use onl
Slide 12: Four Key Areas
rsonal use only Four Key Areas:
Slide 13: Growth Strategy driven by four product segments
Growth Strategy driven by four product segments rsonal use only
Slide 14: Product/Solutions, application, problem solved, ROI, pricing
rsonal use only Product/ Solutions Application Problem Solved ROI Pricing/Scale Diagnostic Technology Coding Assistance and Data Quality Clinical Decision Support (CDS) Collaborative Partnerships Analytics & Knowledge Networks
Slide 15: FY22 Highlights
FY22 Highlights
Slide 16: FY22 growth metrics versus PCP
rsonal use only 172% 97% 43% PCP* PCP PCP** * Prior Corresponding Period “PCP” ** Excludes impact of large one off advisory contract which had 60% of revenue in FY21, 40% in FY22. PCP growth would be 14% if this contract was included
Slide 17: FY22 Key Strategic Highlights
FY22 Key Strategic Highlights Two important acquisitions completed in FY22, doubling the size of Beamtree 1. Acquisition of Potential(x) in Sept 2021, one of Australia’s largest health data analytics company 2. Acquisition of Ainsoff to drive Al product innovation and add to our clinical decision su
Slide 18: Highlights of FY22
Highlights of FY22 9 20" 480% Ue Group with 200+ attendees @ UK contracts for decision support in NHS hospitals Production of new BI Platform @ Extension of First contract to trial for hospital-acquired RippleDown® Ainsoff Index™ in complications global distribution Hong Kong partnership New trial p
Slide 19: FY23 Update and Outlook
FY23 Update and Outlook
Slide 20: FY23 YTD Trading Update
FY23 YTD Trading Update \Clini¢al Decision _Support (CDS) ’ (Rtialytics & LY Kpowledge Networks Australia: Our first contract implementation with Healius Limited, beginning with Western Diagnostics in Perth, in partnership with Abbott Laboratories. UK: The first implementation of RippleDown® in NHS
Slide 21: FY23 outlook: revenue, margin, costs, M&A
• rsonal use only Revenue • • • • • Margin • • • Costs/Cash • • • • • M&A • All outlook statements are subject to ongoing uncertainty in relation to variability in market access conditions should COVID-19 pandemic related measures change in relevant markets and broader economic and geopolitical unce
Slide 22: ARR target and segment contribution 2022 to 2026
rsonal use only ARR* $60M Revenue 35% CAGR Contribution % ~35-40% ARR* $18M ~15-20% ~15-20% ~30% <5% ~25% ~30% ~45% Analytics & Knowledge Networks Coding Assistance and Data Quality 2022 Clinical Decision Support (CDS) Diagnostic Technology 2026 * Annual recurring revenue “ARR”
Slide 23: rsonal use only
0) ro) C pb & (@) ) Ajuo Bsn jeuosia
Beamtree Holdings — Shareholder Meeting (November 2022) on 6ix